v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Aug. 31, 2022
Aug. 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Income Statement [Abstract]        
Collaboration revenue $ 10,791,000 $ 10,252,000 $ 31,844,000 $ 22,354,000
Operating expenses:        
Research and development 47,761,000 30,906,000 138,391,000 79,903,000
General and administrative 9,748,000 8,343,000 28,630,000 22,384,000
Total operating expenses 57,509,000 39,249,000 167,021,000 102,287,000
Loss from operations (46,718,000) (28,997,000) (135,177,000) (79,933,000)
Interest and other income, net 1,009,000 39,000 1,534,000 528,000
Loss before income taxes (45,709,000) (28,958,000) (133,643,000) (79,405,000)
Provision for (benefit from) income taxes 0 (123,000) 0 87,000
Net loss $ (45,709,000) $ (28,835,000) $ (133,643,000) $ (79,492,000)
Net loss per share, basic $ (0.90) $ (0.65) $ (2.85) $ (1.88)
Weighted-average number of shares outstanding, basic [1] 50,868,542 44,374,389 46,835,776 42,344,420
Net loss per share, diluted $ (0.90) $ (0.65) $ (2.85) $ (1.88)
Weighted-average number of shares outstanding, diluted [1] 50,868,542 44,374,389 46,835,776 42,344,420
[1] The shares underlying the pre-funded warrants to purchase an aggregate of 6,814,920 shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended August 31, 2022.